Literature DB >> 24990146

A high-content assay for identifying small molecules that reprogram C. elegans germ cell fate.

Joshua A Benson1, Erin E Cummings1, Linda P O'Reilly1, Myon-Hee Lee2, Stephen C Pak3.   

Abstract

Recent breakthrough discoveries have shown that committed cell fates can be reprogrammed by genetic, chemical and environmental manipulations. The germline of the nematode Caenorhabditis elegans provides a tractable system for studying cell fate reprogramming within the context of a whole organism. To explore the possibility of using C. elegans in high-throughput screens (HTS), we developed a high-throughput workflow for testing compounds that modulate cell fate reprogramming. We utilized puf-8; lip-1 mutants that have enhanced MPK-1 (an ERK homolog)/MAP kinase (MAPK) signaling. Wild-type C. elegans hermaphrodites produce both sperm and oocytes, and are thus self-fertile. However, puf-8; lip-1 mutants produce only sperm and are sterile. Notably, compounds that pharmacologically down-regulate MPK-1 (an ERK homolog)/MAP kinase (MAPK) signaling are able to reprogram germ cell fate and restore fertility to these animals. puf-8; lip-1 mutants provide numerous challenges for HTS. First, they are sterile as homozygotes and must be maintained as heterozygotes using a balancer chromosome. Second, homozygous animals for experimentation must be physically separated from the rest of the population. Third, a high quality, high-content assay has not been developed to measure compound effects on germ cell fate reprogramming. Here we describe a semi-automated high-throughput workflow that enables effective sorting of homozygous puf-8; lip-1 mutants into 384-well plates using the COPAS™ BIOSORT. In addition, we have developed an image-based assay for rapidly measuring germ cell reprogramming by measuring the number of viable progeny in wells. The methods presented in this report enable the use of puf-8; lip-1 mutants in HTS campaigns for chemical modulators of germ cell reprogramming within the context of a whole organism.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  C. elegans; Cell fate; Drug screening; High-content screening; Reprogramming

Mesh:

Substances:

Year:  2014        PMID: 24990146     DOI: 10.1016/j.ymeth.2014.05.011

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  6 in total

1.  Expanding the C. elegans toolbox into a toolshed.

Authors:  Arjumand Ghazi; Judith Yanowitz; Gary A Silverman
Journal:  Methods       Date:  2014-08-01       Impact factor: 3.608

Review 2.  Natural diversity facilitates the discovery of conserved chemotherapeutic response mechanisms.

Authors:  Stefan Zdraljevic; Erik C Andersen
Journal:  Curr Opin Genet Dev       Date:  2017-09-09       Impact factor: 5.578

3.  A Phenotype-Based RNAi Screening for Ras-ERK/MAPK Signaling-Associated Stem Cell Regulators in C. elegans.

Authors:  Myon-Hee Lee; Dong Suk Yoon
Journal:  Methods Mol Biol       Date:  2017

Review 4.  Caenorhabditis elegans: A Model System for Anti-Cancer Drug Discovery and Therapeutic Target Identification.

Authors:  Robert A Kobet; Xiaoping Pan; Baohong Zhang; Stephen C Pak; Adam S Asch; Myon-Hee Lee
Journal:  Biomol Ther (Seoul)       Date:  2014-09-30       Impact factor: 4.634

5.  Combined flow cytometry and high-throughput image analysis for the study of essential genes in Caenorhabditis elegans.

Authors:  Blanca Hernando-Rodríguez; Annmary Paul Erinjeri; María Jesús Rodríguez-Palero; Val Millar; Sara González-Hernández; María Olmedo; Bettina Schulze; Ralf Baumeister; Manuel J Muñoz; Peter Askjaer; Marta Artal-Sanz
Journal:  BMC Biol       Date:  2018-03-29       Impact factor: 7.431

6.  Developmental Effects of the ToxCast™ Phase I and Phase II Chemicals in Caenorhabditis elegans and Corresponding Responses in Zebrafish, Rats, and Rabbits.

Authors:  Windy A Boyd; Marjolein V Smith; Caroll A Co; Jason R Pirone; Julie R Rice; Keith R Shockley; Jonathan H Freedman
Journal:  Environ Health Perspect       Date:  2015-10-23       Impact factor: 9.031

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.